New insights into human 5-HT 4 receptor binding site: Exploration of a hydrophobic pocket

British Journal of Pharmacology

Volumn 143, Issue 3, 2004, Pages 361-370

  Rivail, Lucie ^a   Giner, Mireille ^a   Gastineau, Monique ^b   Berthouze, Magali ^b   Soulier, Jean Louis ^a   Fischmeister, Rodolphe ^b   Lezoualc'h, Frank ^b   Maigret, Bernard ^c   Sicsic, Sames ^a   Berque Bestel, Isabelle ^a  

^a UNIVERSITÉ PARIS SUD   (France)

^b INSERM   (France)

^c NANCY UNIVERSITÉ   (France)

Author keywords

5 HT 4 bulky ligands; 5 HT 4 receptor; Hydrophobic pocket; Molecular modelling; Site directed mutagenesis

Indexed keywords

1 (8 AMINO 7 CHLORO 2,3 DIHYDROBENZO[1,4]DIOXIN 5 YL) 3 [1 [3 (3,4 DIMETHOXYPHENYL)PROPYL]PIPERIDIN 4 YL]PROPAN 1 ONE; 1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (3,5 DIMETHYLPIPERIDIN 1 YL)ETHYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (3,5 DIMETHYLPIPERIDINO)ETHYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 [4 [4 (5 DIMETHYLAMINONAPHTHALENE 1 SULFONYLAMINO)BUTYL]PIPERIDIN 1 YL]ETHYL ESTER; ADENYLATE CYCLASE; CYCLIC AMP; ML 11411; N [2 [4 [3 [4 AMINO 5 CHLORO 2 (3,5 DIMETHOXYBENZYLOXY)PHENYL] 3 OXOPROPYL]PIPERIDIN 1 YL]ETHYL]METHANESULFONAMIDE; RS 100235; RS 39604; SEROTONIN; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CONTROLLED STUDY; DRUG BINDING SITE; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

AMINO ACIDS; AMINOBENZOIC ACIDS; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; HYDROPHOBICITY; INDOLES; MODELS, MOLECULAR; MUTATION; PIPERIDINES; PROPANE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RADIOLIGAND ASSAY; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SULFONAMIDES; TRITIUM;

EID: 7044285782     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705950     Document Type: Article

References (43)

1. BALLESTEROS, J. & WEINSTEIN, H. (1995). Integrated methods for the construction of three-dimensional models of structure-function relations in G protein-coupled receptor. Methods Neurosci., 25, 366-428.
2. BALLESTEROS, J.A., SHI, L. & JAVITCH, J.A. (2001). Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol., 60, 1-19.
3. BECK-SICKINGER, A.G. (1996). Structural characterization and binding sites of G-protein-coupled receptors. DDT, 1, 502-513.
4. 4 receptors. J. Med. Chem., 46, 2606-2620.
5. 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem., 70, 2252-2261.
6. 4 agonist, prucalopride, in healthy humans. Gut, 44, 682-686.
7. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantity of protein utilising the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
8. 4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem., 38, 2326-2330.
9. 4 receptor. J. Chem. Inform. Comput. Sci., 42, 962-967.
10. 4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J. Biol. Chem., 278, 699-702.
11. 4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol., 55, 910-920.
12. 4 receptor antagonist. Bioorg. Med. Chem. Lett., 5, 2119-2122.
13. 4 receptor antagonists. Bioorg. Med. Chem. Lett., 4, 2481-2484.
14. 4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch. Pharmacol., 340, 403-410.
15. 3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro. Br. J. Pharmacol., 101, 513-520.
16. 2 receptor accessible in the binding-site crevice. Biochemistry, 35, 11278-11285.
17. 4 receptor antagonists. Med. Res. Rev., 17, 163-214.
18. 2 adrenoceptor. EMBO J., 16, 6737-6747.
19. 4 receptors. FASEB J., 10, 1398-1407.
20. HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYLECHARANE, E.J., SAXENA, P.R. & HUMPHREY, P.P. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46, 157-203.
21. 4 agonist activities using molecular field analysis. J. Chem. Soc. Perkin Trans., 2, 153-158.
22. 4 receptors mediate arrhythmias? Trends Pharmacol. Sci., 15, 451-455.
23. 2-adrenergic receptor by fluorescence spectroscopy. Adv. Pharmacol., 42, 470-473.
24. KONVICKA, K., GUARNIERI, F., BALLESTEROS, J.A. & WEINSTEIN, H. (1998). A proposed structure for transmembrane segment 7 of G protein-coupled receptors incorporating an Asn-Pro/Asp-Pro motif. Biophys. J., 75, 601-611.
25. 2c receptor interaction. Eur. J. Pharmacol., 306, 195-210.
26. 4 receptor ligands: applications and new prospects. J. Med. Chem., 46, 319-344.
27. LASKOWSKI, R.A. (1995). SURFNET: a program for visualizing molecular surfaces, cavities and intermolecular interactions. J. Mol. Graph., 13, 323-330.
28. 4 receptor antagonists: structure-affinity relationships and ligand-receptor interactions. Curr. Top. Med. Chem., 2, 625-641.
29. 4 binding sites. J. Comput. Aided Mol. Des., 11, 589-599.
30. 4 receptor guided by site-directed mutagenesis and the crystal structure of rhodopsin. J. Comput. Aided Mol. Des., 15, 1025-1033.
31. 4 receptors: a novel therapeutic target for Alzheimer's disease? Curr. Alzheimer Res., 1, 79-86.
32. 4 receptors. Neuropharmacology, 36, 697-706.
33. 4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br. J. Pharmacol., 129, 771-781.
34. 4 receptor by site-directed mutagenesis and molecular modeling. Br. J. Pharmacol., 130, 527-538.
35. PALCZEWSKI, K., KUMASAKA, T., HORI, T., BEHNKE, C.A., MOTOSHIMA, H., FOX, B.A., LE TRONG, I., TELLER, D.C., OKADA, T., STENKAMP, R.E., YAMAMOTO, M. & MIYANO, M. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science, 289, 739-745.
36. PAUWELS, P.J. (2003). Unravelling multiple ligand-activation binding sites using RASSL receptors. Trends Pharmacol. Sci., 24, 504-507.
37. 4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem., 276, 44881-44888.
38. 2A receptors. Mol. Pharmacol., 52, 259-266.
39. SAKMAR, T.P., MENON, S.T., MARIN, E.P. & AWAD, E.S. (2002). Rhodopsin: insights from recent structural studies. Annu. Rev. Biophys. Biomol. Struct., 31, 443-484.
40. SCHWARTZ, T.W., GETHER, U., SCHAMBYE, H.T. & HJORTH, S.A. (1995). Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr. Pharm. Des., 1, 325-342.
41. 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J. Biol. Chem., 277, 11441-11449.
42. STRADER, C.D., SIGAL, I.S. & DIXON, R.A. (1989). Structural basis of beta-adrenergic receptor function. FASEB J., 3, 1825-1832.
43. 4 receptors. J. Med. Chem., 40, 608-621.